SEATTLE, May 19, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced that data highlighting pacritinib, including additional safety and long-term follow up data from the Phase 3 PERSIST-1 clinical trial, will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3-7 in Chicago, IL. The abstracts are available on the ASCO website at www.asco.org. Details regarding the poster presentations, which will include additional data not available in the abstracts, follow.
Pacritinib (PAC) vs. best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia
First Author: Claire Harrison, M.D., Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London, United Kingdom
Date/Time: Monday, June 6 at 8:00 a.m.-11:30 a.m. CT
Poster Discussion Session: Monday, June 6, 11:30 a.m.-12:45 p.m. CT in Room E354b
Location: Hall A
Poster Session: Hematologic Malignancies- Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract #7011 / Poster Board #3
Pacritinib (PAC) vs. best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial
First Author: Ruben Mesa, M.D., Mayo Clinic Cancer Center, Chair of the Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ
Date/Time: Monday, June 6 at 8:00 a.m.-11:30 a.m. CT
Location: Hall A
Poster Session: Hematologic Malignancies- Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract #7065 / Poster Board #57
Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy
First Author: Claire Harrison, M.D., Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London, United Kingdom
Date/Time: Monday, June 6 at 8:00 a.m.-11:30 a.m. CT
Location: Hall A
Poster Session: Hematologic Malignancies- Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract #7066 / Poster Board #58
Pacritinib (PAC) vs. best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial
First Author: Ruben Mesa, M.D., Mayo Clinic Cancer Center, Chair of the Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ
Date/Time: Monday, June 6 at 8:00 a.m.-11:30 a.m. CT
Location: Hall A
Poster Session: Hematologic Malignancies- Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract #7067 / Poster Board #59
About Pacritinib
Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. In August 2014, pacritinib was granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis including, but not limited to, patients with disease-related thrombocytopenia (low platelet counts); patients experiencing treatment-emergent thrombocytopenia on other JAK2 inhibitor therapy; or patients who are intolerant of, or whose symptoms are not well controlled (sub-optimally managed) on other JAK2 therapy. Clinical studies for pacritinib are currently subject to a full clinical hold issued by the U.S. Food and Drug Administration in February 2016.
CTI BioPharma and Baxalta Incorporated are parties to a worldwide license agreement to develop and commercialize pacritinib. CTI BioPharma and Baxalta will jointly commercialize pacritinib in the U.S. while Baxalta has exclusive commercialization rights for all indications outside the U.S.
About CTI BioPharma Corp.
CTI BioPharma Corp. (NASDAQ and MTA:CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe with respect to PIXUVRI® and a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.
PIXUVRI is a registered trademark of CTI BioPharma Corp.
Contacts:
Monique Greer
+1 206-272-4343
mgreer@ctibiopharma.com
Ed Bell
+1 206-272-4345
ebell@ctibiopharma.com
Logo - http://photos.prnewswire.com/prnh/20140529/92480
SOURCE CTI BioPharma Corp.